Annual EBITDA
-$20.57 M
-$8.45 M-69.72%
September 1, 2024
Summary
- As of February 7, 2025, CTOR annual EBITDA is -$20.57 million, with the most recent change of -$8.45 million (-69.72%) on September 1, 2024.
- During the last 3 years, CTOR annual EBITDA has fallen by -$15.72 million (-323.60%).
- CTOR annual EBITDA is now -323.60% below its all-time high of -$4.86 million, reached on September 1, 2022.
Performance
CTOR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CTOR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -69.7% | - | - |
| 3 y3 years | -323.6% | - | - |
| 5 y5 years | -323.6% | - | - |
CTOR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -323.6% | at low | ||||
| 5 y | 5-year | -323.6% | at low | ||||
| alltime | all time | -323.6% | at low |
Citius Oncology EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$20.57 M(+69.7%) | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | -$12.12 M(+149.6%) | - | - |
| Sep 2022 | -$4.86 M | - | - |
FAQ
- What is Citius Oncology annual EBITDA?
- What is the all time high annual EBITDA for Citius Oncology?
- What is Citius Oncology annual EBITDA year-on-year change?
What is Citius Oncology annual EBITDA?
The current annual EBITDA of CTOR is -$20.57 M
What is the all time high annual EBITDA for Citius Oncology?
Citius Oncology all-time high annual EBITDA is -$4.86 M
What is Citius Oncology annual EBITDA year-on-year change?
Over the past year, CTOR annual EBITDA has changed by -$8.45 M (-69.72%)